Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Oct 6;2015(10):CD010057.
doi: 10.1002/14651858.CD010057.pub2.

Citrate salts for preventing and treating calcium containing kidney stones in adults

Rebecca Phillips  1 , Vishwanath S Hanchanale, Andy Myatt, Bhaskar Somani, Ghulam Nabi, C Shekhar Biyani
Affiliations
Review

Citrate salts for preventing and treating calcium containing kidney stones in adults

Rebecca Phillips et al. Cochrane Database Syst Rev. .

Abstract

Background: Kidney stones affect people worldwide and have a high rate of recurrence even with treatment. Recurrences are particularly prevalent in people with low urinary citrate levels. These people have a higher incidence of calcium phosphate and calcium oxalate stones. Oral citrate therapy increases the urinary citrate levels, which in turn binds with calcium and inhibits the crystallisation thus reduces stone formation. Despite the widespread use of oral citrate therapy for prevention and treatment of calcium oxalate stones, the evidence to support its clinical efficacy remains uncertain.

Objectives: The objective of this review was to determine the efficacy and adverse events associated with citrate salts for the treatment and prevention of calcium containing kidney stones.

Search methods: We searched the Cochrane Kidney and Transplant Specialised Register to 29 July 2015 through contact with the Trials' Search Co-ordinator using search terms relevant to this review.

Selection criteria: We included randomised controlled trials (RCTs) that assessed the efficacy and adverse events associated with citrate salts for the treatment and prevention of calcium containing kidney stones in adults treated for a minimum of six months.

Data collection and analysis: Two authors assessed studies for inclusion in this review. Data were extracted according to predetermined criteria. Summary estimates of effect were obtained using a random-effects model, and results were expressed as risk ratios (RR) and their 95% confidence intervals (CI) for dichotomous outcomes, and mean difference (MD) and 95% CI for continuous outcomes.

Main results: We included seven studies that included a total of 477 participants, most of whom had oxalate stones. Of these, three studies (247 participants) compared potassium citrate with placebo or no intervention; three (166 participants) compared potassium-sodium citrate with no intervention; and one (64 participants) compared potassium-magnesium citrate with placebo. Overall, quality of the reporting of the included studies was considered moderate to poor, and there was a high risk of attrition bias in two studies.Compared with placebo or no intervention, citrate therapy significantly reduced the stone size (4 studies, 160 participants: RR 2.35, 95% CI 1.36 to 4.05). New stone formation was significantly lower with citrate therapy compared to control (7 studies, 324 participants: RR 0.26, 95% CI 0.10 to 0.68). The beneficial effect on stone size stability was also evident (4 studies, 160 participants: RR 1.97, 95% CI 1.19 to 3.26). Adverse events were reported in four studies, with the main side effects being upper gastrointestinal disturbance and one patient reported a rash. There were more gastrointestinal adverse events in the citrate group; however this was not significant (4 studies, 271 participants: RR 2.55, 95% CI 0.71 to 9.16). There were significantly more dropouts due to adverse events with citrate therapy compared to control (4 studies, 271 participants: RR 4.45, 95% CI 1.28 to 15.50). The need for retreatment was significantly less with citrate therapy compared to control (2 studies, 157 participants: RR 0.22, 95% CI 0.06 to 0.89).

Authors' conclusions: Citrate salts prevent new stone formation and reduce further stone growth in patients with residual stones that predominantly contain oxalate. The quality of reported literature remains moderate to poor; hence a well-designed statistically powered multi-centre RCT is needed in order to answer relevant questions concerning the efficacy of citrate salts.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1
1
Flow diagram showing article selection process
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1 Citrate salts versus placebo or no intervention, Outcome 1 Reduction in stone size.
1.2
1.2. Analysis
Comparison 1 Citrate salts versus placebo or no intervention, Outcome 2 New stone formation.
1.3
1.3. Analysis
Comparison 1 Citrate salts versus placebo or no intervention, Outcome 3 Stone size stability.
1.4
1.4. Analysis
Comparison 1 Citrate salts versus placebo or no intervention, Outcome 4 Urinary citrate levels.
1.5
1.5. Analysis
Comparison 1 Citrate salts versus placebo or no intervention, Outcome 5 Adverse events.
1.6
1.6. Analysis
Comparison 1 Citrate salts versus placebo or no intervention, Outcome 6 Dropouts.
1.7
1.7. Analysis
Comparison 1 Citrate salts versus placebo or no intervention, Outcome 7 Retreatment.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD010057

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Barcelo 1993 {published data only}
    1. Barcelo P, Wuhl O, Servitge E, Rousaud A, Pak CY. Randomized double‐blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. Journal of Urology 1993;150(6):1761‐4. [MEDLINE: ] - PubMed
Cicerello 1994 {published data only}
    1. Cicerello E, Merlo F, Gambaro G, Maccatrozzo L, Fandella A, Baggio B, et al. Effect of alkaline citrate therapy on clearance of residual renal stone fragments after extracorporeal shock wave lithotripsy in sterile calcium and infection nephrolithiasis patients. Journal of Urology 1994;151(1):5‐9. [MEDLINE: ] - PubMed
Ettinger 1997 {published data only}
    1. Ettinger B, Pak CY, Citron JT, Thomas C, Adams‐Huet B, Vangessel A. Potassium‐Magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. Journal of Urology 1997;158(6):2069‐73. [MEDLINE: ] - PubMed
Hofbauer 1994 {published data only}
    1. Hofbauer J, Hobarth K, Szabo N, Marberger M. Alkali citrate prophylaxis in idiopathic recurrent calcium oxalate urolithiasis‐‐a prospective randomized study. British Journal of Urology 1994;73(4):362‐5. [MEDLINE: ] - PubMed
Jimenez Verdejo 2001 {published data only}
    1. Jimenez Verdejo A, Arrabal Martin M, Mijan Ortiz JL, Hita Rosino E, Palao Yago F, Zuluaga Gomez A. Effect of potassium citrate in the prophylaxis of urinary lithiasis [Efecto del citrato potasico en la profilaxis de la litiasis urinaria]. Archivos Espanoles de Urologia 2001;54(9):1036‐46. [MEDLINE: ] - PubMed
Lojanapiwat 2011 {published data only}
    1. Lojanapiwat B, Tanthanuch M, Pripathanont C, Ratchanon S, Srinualnad S, Taweemonkongsap T, et al. Alkaline citrate reduces stone recurrence and regrowth after shockwave lithotripsy and percutaneous nephrolithotomy. International Brazilian Journal of Urology 2011;37(5):611‐6. [MEDLINE: ] - PubMed
    1. Lojanapiwat B, Tanthanuch M, Pripathanont C, Ratchanon S, Srinualnad S, Taweemonkongsap T, et al. Effect of alkaline citrate on stone recurrence and regrowth after shock wave lithotripsy and percutaneous nephrolithotomy in calcium urolithiasis: A randomised controlled trial [abstract]. Archivio Italiano di Urologia e Andrologia 2009;81(3):141. [EMBASE: 70036858]
Soygur 2002 {published data only}
    1. Soygur T, Akbay A, Kupeli S. Effect of potassium citrate therapy on stone recurrence and residual fragments after shockwave lithotripsy in lower caliceal calcium oxalate urolithiasis: a randomized controlled trial. Journal of Endourology 2002;16(3):149‐52. [MEDLINE: ] - PubMed

References to studies excluded from this review

Allie‐Hamdulay 2005 {published data only}
    1. Allie‐Hamdulay S, Rodgers AL. Prophylactic and therapeutic properties of a sodium citrate preparation in the management of calcium oxalate urolithiasis: randomized, placebo‐controlled trial. Urological Research 2005;33(2):116‐24. [MEDLINE: ] - PubMed
Aras 2008 {published data only}
    1. Aras B, Kalfazade N, Tugcu V, Kemahli E, Ozbay B, Polat H, et al. Can lemon juice be an alternative to potassium citrate in the treatment of urinary calcium stones in patients with hypocitraturia? A prospective randomized study. Urological Research 2008;36(6):313‐7. [MEDLINE: ] - PubMed
Brardi 2012 {published data only}
    1. Brardi S, Imperiali P, Cevenini G, Verdacchi T, Ponchietti R. Effects of the association of potassium citrate and agropyrum repens in renal stone treatment: results of a prospective randomized comparison with potassium citrate. Archivio Italiano di Urologia, Andrologia 2012;84(2):61‐7. [MEDLINE: ] - PubMed
El‐Gamal 2012 {published data only}
    1. El‐Gamal O, El‐Bendary M, Ragab M, Rasheed M. Role of combined use of potassium citrate and tamsulosin in the management of uric acid distal ureteral calculi. Urological Research 2012;40(3):219‐24. [MEDLINE: ] - PubMed
    1. Elbenday M, Elgamal O, Elbadry A, Attia M. Role of combined use of potassium citrate and tamsulosin in the management of uric acid distal ureteral calculi [abstract no: 1317]. Journal of Urology 2010;183(4 Suppl 1):e509. [EMBASE: 70144990]
Ettinger 1976 {published data only}
    1. Ettinger B. Recurrent nephrolithiasis: natural history and effect of phosphate therapy. A double‐blind controlled study. American Journal of Medicine 1976;61(2):200‐6. [MEDLINE: ] - PubMed
Fernandez Rodriguez 2001 {published data only}
    1. Fernandez Rodrigues A, Arrabal Martin M, Garcia Ruiz MJ, Haro Munoz T, Zuluaga Gomez A. Effect of thiazide therapy in the prophylaxis of calcium lithiasis [Efecto de las tiazidas en la profilaxis de la litiasis calcica]. Archivos Espanoles de Urologia 2001;54(9):1047‐54. [MEDLINE: ] - PubMed
    1. Fernandez‐Rodriguez A, Arrabal‐Martin M, Garcia‐Ruiz MJ, Arrabal‐Polo MA, Pichardo‐Pichardo S, Zuluaga‐Gomez A. The role of thiazides in the prophylaxis of recurrent calcium lithiasis [Papel de las tiazidas en la profilaxis de la litiasis calcica recidivante]. Actas Urologicas Espanolas 2006;30(3):305‐9. [MEDLINE: ] - PubMed
Gao 2010 {published data only}
    1. Gao J, Shen Y, Sun N, Jia LQ, Pan YS, Sun Q. Therapeutic effects of potassium sodium hydrogen citrate on melamine‐induced urinary calculi in China. Chinese Medical Journal 2010;123(9):1112‐6. [MEDLINE: ] - PubMed
He 2004a {published data only}
    1. He HC, Zhong WD, Xie KJ, Dai QS, Zeng GQ, Wei H, et al. Effects of potassium citrate delayed preparation in urine PH and citric acid content. Chung‐Hua i Hsueh Tsa Chih [Chinese Medical Journal] 2004;84(21):1825‐6. [MEDLINE: ] - PubMed
Heguilen 2005 {published data only}
    1. Heguilen RM, Bellusci AD, Bernasconi AR. Differential impact of potassium citrate and hydrochlorothiazide in hypercalciuric patients [abstract no: TH‐PO877]. Journal of the American Society of Nephrology 2005;16:311A.
Jaipakdee 2004 {published data only}
    1. Jaipakdee S, Prasongwatana V, Premgamone A, Reungjui S, Tosukhowong P, Tungsanga K, et al. The effects of potassium and magnesium supplementations on urinary risk factors of renal stone patients. Journal of the Medical Association of Thailand 2004;87(3):255‐63. [MEDLINE: ] - PubMed
Kato 2004 {published data only}
    1. Kato Y, Yamaguchi S, Yachiku S, Nakazono S, Hori J, Wada N, et al. Changes in urinary parameters after oral administration of potassium‐sodium citrate and magnesium oxide to prevent urolithiasis. Urology 2004;63(1):7‐11. [MEDLINE: ] - PubMed
Khanniazi 1993 {published data only}
    1. Khanniazi MK, Khanam A, Naqvi SA, Sheikh MA. Study of potassium citrate treatment of crystalluric nephrolithiasis. Biomedical Pharmacotherapy 1993;47(1):25‐8. [MEDLINE: ] - PubMed
Koff 2007 {published data only}
    1. Koff SG, Paquette EL, Cullen J, Gancarczyk KK, Tucciarone PR, Schenkman NS. Comparison between lemonade and potassium citrate and impact on urine pH and 24‐hour urine parameters in patients with kidney stone formation. Urology 2007;69(6):1013‐6. [MEDLINE: ] - PubMed
Lee 1999 {published data only}
    1. Lee YH, Huang WC, Tsai JY, Huang JK. The efficacy of potassium citrate based medical prophylaxis for preventing upper urinary tract calculi: a midterm followup study. Journal of Urology 1999;161(5):1453‐7. [MEDLINE: ] - PubMed
LIMONE Study 2012 {published data only}
    1. Ruggenenti P. A prospective, randomised, open blind endpoint (probe) trial to assess the possibility to prevent stone recurrence by lemon juice supplementation in patients with recurrent calcium oxalate nephrolithiasis (LIMONE Study). www.clinicaltrials.gov/show/NCT01217372 (accessed 29 July 2015).
Mechlin 2011 {published data only}
    1. Mechlin C, Kalorin C, Asplin J, White M. Splenda improves tolerance of oral potassium citrate supplementation for prevention of stone formation: results of a randomized double‐blind trial. Journal of Endourology 2011;25(9):1541‐5. [MEDLINE: ] - PubMed
    1. Mechlin CW, Kalorin C, Asplin J, White MD. Splenda improves tolerance of oral potassium citrate supplementation: results of a randomized double blind trial [abstract no: PS25‐8]. Journal of Endourology 2010;24(Suppl 1):A197. [EMBASE: 70295603] - PubMed
Mortensen 1986 {published data only}
    1. Mortensen JT, Schultz A, Ostergaard AH. Thiazides in the prophylactic treatment of recurrent idiopathic kidney stones. International Urology & Nephrology 1986;18(3):265‐9. [MEDLINE: ] - PubMed
Pak 1992 {published data only}
    1. Pak CY, Koenig K, Khan R, Haynes S, Padalino P. Physicochemical action of potassium‐magnesium citrate in nephrolithiasis. Journal of Bone & Mineral Research 1992;7(3):281‐5. [MEDLINE: ] - PubMed
Pearle 2002 {published data only}
    1. Pearle MS. Effect of potassium citrate therapy on stone recurrence and residual fragments after shockwave lithotripsy in lower caliceal calcium oxalate urolithiasis: a randomized controlled trial. International Brazilian Journal of Urology 2002;28(6):570‐1. [MEDLINE: ] - PubMed
Pinheiro 2013 {published data only}
    1. Pinheiro VB, Baxmann AC, Tiselius HG, Heilberg IP. The effect of sodium bicarbonate upon urinary citrate excretion in calcium stone formers. Urology 2013;82(1):33‐7. [MEDLINE: ] - PubMed
Premgamone 2001 {published data only}
    1. Premgamone A, Sriboonlue P, Disatapornjaroen W, Maskasem S, Sinsupan N, Apinives C. A long‐term study on the efficacy of a herbal plant, Orthosiphon grandiflorus, and sodium potassium citrate in renal calculi treatment. Southeast Asian Journal of Tropical Medicine & Public Health 2001;32(3):654‐60. [MEDLINE: ] - PubMed
Preminger 1988 {published data only}
    1. Preminger GM, Sakhaee K, Pak CY. Alkali action on the urinary crystallization of calcium salts: contrasting responses to sodium citrate and potassium citrate. Journal of Urology 1988;139(2):240‐2. [MEDLINE: ] - PubMed
Sakhaee 1983 {published data only}
    1. Sakhaee K, Nicar M, Hill K, Pak CY. Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone‐forming salts. Kidney International 1983;24(3):348‐52. [MEDLINE: ] - PubMed
Sakhaee 2004 {published data only}
    1. Sakhaee K, Poindexter JR, Griffith CS, Pak CY. Stone forming risk of calcium citrate supplementation in healthy postmenopausal women. Journal of Urology 2004;172(3):958‐61. [MEDLINE: ] - PubMed
Sarica 2006a {published data only}
    1. Sarica K, Erturhan S, Yurtseven C, Yagci F. Effect of potassium citrate therapy on stone recurrence and regrowth after extracorporeal shockwave lithotripsy in children. Journal of Endourology 2006;20(11):875‐9. [MEDLINE: ] - PubMed
Schell‐Feith 2006 {published data only}
    1. Schell‐Feith EA, Moerdijk A, Zwieten PH, Zonderland HM, Holscher HC, Kist‐van Holthe J, et al. Does citrate prevent nephrocalcinosis in preterm neonates?. Pediatric Nephrology 2006;21(12):1830‐6. [MEDLINE: ] - PubMed
See 2012 {published data only}
    1. See M, Chua M, Luna S. A prospective 6‐weeks randomized controlled trial to evaluate the efficacy and safety of sodium bicarbonate, citric acid, sodium citrate, and tartaric acid compound compared to potassium citrate in the treatment of renal stones [abstract no: 2259]. Journal of Urology 2012;187(4 Suppl 1):e911‐2. [EMBASE: 70721953]
    1. See MC, Chua ME, Luna S. A prospective 6‐week randomized controlled trial to evaluate the efficacy and safety of NA bicarbonate, citric acid, NA citrate, and tartaric acid coumpound drug compared to potassium citrate in the dissolution of renal stones [abstract]. Journal of Endourology 2012;26(Suppl 1):A8. [EMBASE: 70875588]
Singh 2010 {published data only}
    1. Singh RG, Behura SK, Kumar R. Litholytic property of Kulattha (Dolichous biflorus) vs potassium citrate in renal calculus disease: a comparative study. Journal of the Association of Physicians of India 2010;58:286‐9. [MEDLINE: ] - PubMed
Singh 2011a {published data only}
    1. Singh I, Bishnoi I, Agarwal V, Bhatt S. Prospective randomized clinical trial comparing phytotherapy with potassium citrate in management of minimal burden (<8 mm) nephrolithiasis. Urology Annals 2011;3(2):75‐81. [MEDLINE: ] - PMC - PubMed
Singh 2012 {published data only}
    1. Singh RG, Singh TB, Kumar R, Dwivedi US, Moorthy KN, Kumar N. A comparative pilot study of litholytic properties of celosia argental (Sitivaraka) versus potassium citrate in renal calculus disease. Journal of Alternative & Complementary Medicine 2012;18(5):427‐8. [MEDLINE: ] - PubMed
Tosukhowong 2008 {published data only}
    1. Tosukhowong P, Yachantha C, Sasivongsbhakdi T, Ratchanon S, Chaisawasdi S, Boonla C, et al. Citraturic, alkalinizing and antioxidative effects of limeade‐based regimen in nephrolithiasis patients. Urological Research 2008;36(3‐4):149‐55. [MEDLINE: ] - PubMed
Zerwekh 2007 {published data only}
    1. Zerwekh JE, Odvina CV, Wuermser LA, Pak CY. Reduction of renal stone risk by potassium‐magnesium citrate during 5 weeks of bed rest. Journal of Urology 2007;177(6):2179‐84. [MEDLINE: ] - PubMed

References to studies awaiting assessment

Krishna Reddy 2014 {published data only}
    1. Krishna RS, Shaik AB, Bokkisam S. Effect of potassium magnesium citrate and vitamin B‐6 prophylaxis for recurrent and multiple calcium oxalate and phosphate urolithiasis. Korean Journal of Urology 2014;55(6):411‐6. [MEDLINE: ] - PMC - PubMed

References to ongoing studies

NCT01754779 {published data only}
    1. Maalouf NM. Pharmacological therapy for calcium phosphate urolithiasis. clinicaltrials gov/ct2/show/NCT01754779 (accessed 29 July 2015).

Additional references

Fan 2001
    1. Fan J, Schwille PO, Schmiedl A, Fink E, Manoharan M. Calcium oxalate crystallization in undiluted postprandial urine of healthy male volunteers as influenced by citrate. Arzneimittel‐Forschung 2001;51(10):848‐57. [MEDLINE: ] - PubMed
Fink 2012
    1. Fink HA, Wilt TJ, Eidman KE, Garimella PS, MacDonald R, Rutks IR, et al. Recurrent nephrolithiasis in adults: comparative effectiveness of preventive medical strategies. Comparative Effectiveness Review No. 61. AHRQ Publication No. 12‐EHC049‐EF. 2012. effectivehealthcare.ahrq.gov/ehc/products/274/1035/kidney‐stones‐prevent... (accessed 26 August 2015). - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. [MEDLINE: ] - PMC - PubMed
Higgins 2011
    1. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Ito 1992
    1. Ito H, Suzuki F, Yamaguchi K, Nishikawa Y, Kotake T. Reduction of urinary oxalate by combined calcium and citrate administration without increase in urinary calcium oxalate stone formers. Clinical Nephrology 1992;37(1):14‐8. [MEDLINE: ] - PubMed
Kissin 1941
    1. Kissin B, Locks MO. Urinary citrates in calcium urolithiasis. Proceedings of the Society for Experimental Biology & Medicine 1941;46:216‐8.
Kok 1986
    1. Kok DJ, Papapoulos SE, Bijvoet OL. Excessive crystal agglomeration with low citrate excretion in recurrent stone‐formers. Lancet 1986;1(8489):1056‐8. [MEDLINE: ] - PubMed
Levine 1994
    1. Levine BS, Rodman JS, Wienerman S, Bockman RS, Lane JM, Chapman DS. Effect of calcium citrate supplementation on urinary calcium oxalate saturation in female stone formers: implications for prevention of osteoporosis. American Journal of Clinical Nutrition 1994;60(4):592‐6. [MEDLINE: ] - PubMed
Levy 1995
    1. Levy FL, Adams‐Huet B, Pak CY. Ambulatory evaluation of nephrolithiasis: an update of a 1980 protocol. American Journal of Medicine 1995;98(1):50‐9. [MEDLINE: ] - PubMed
Magaret 2007
    1. Magaret SP, Yair L. Urinary lithiasis: diagnosis and medical management. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA editor(s). Campbell's Urology. 9th Edition. Vol. 4, Philadelphia: Saunders, 2007:1363–92.
Mattle 2005
    1. Mattle D, Hess B. Preventive treatment of nephrolithiasis with alkali citrate‐‐a critical review. Urological Research 2005;33(2):73‐9. [MEDLINE: ] - PubMed
Meyer 1975
    1. Meyer JL, Smith LH. Growth of calcium oxalate crystals. II. Inhibition by natural urinary crystal growth inhibitors. Investigative Urology 1975;13(1):36‐9. [MEDLINE: ] - PubMed
Miller 2007
    1. Miller NL, Lingeman JE. Management of kidney stones. BMJ 2007;334(7591):468‐72. [MEDLINE: ] - PMC - PubMed
Nicar 1983
    1. Nicar MJ, Skurla C, Sakhaee K, Pak CY. Low urinary citrate excretion in nephrolithiasis. Urology 1983;21(1):8‐14. [MEDLINE: ] - PubMed
Nowfar 2011
    1. Nowfar S, Palazzi‐Churas K, Chang DC, Sur RL. The relationship of obesity and gender prevalence changes in United States inpatient nephrolithiasis. Urology 2011;78(5):1029‐33. [MEDLINE: ] - PubMed
Pak 1991
    1. Pak CY. Citrate and renal calculi: new insights and future directions. American Journal of Kidney Diseases 1991;17(4):420‐5. [MEDLINE: ] - PubMed
Pak 1994
    1. Pak CY. Citrate and renal calculi: an update. Mineral & Electrolyte Metabolism 1994;20(6):371‐7. [MEDLINE: ] - PubMed
Pak 1998
    1. Pak CY. Kidney stones. Lancet 1998;351(9118):1797‐801. [MEDLINE: ] - PubMed
Pak 2003
    1. Pak CY, Heller HJ, Pearle MS, Odvina CV, Poindexter JR, Peterson RD. Prevention of stone formation and bone loss in absorptive hypercalciuria by combined dietary and pharmacological interventions. Journal of Urology 2003;169(2):465‐9. [MEDLINE: ] - PubMed
Parks 1996
    1. Parks JH, Coe FL. The financial effects of kidney stone prevention. Kidney International 1996;50(5):1706‐12. [MEDLINE: ] - PubMed
Pearle 1999
    1. Pearle MS, Roehrborn CG, Pak CY. Meta‐analysis of randomised trials for medical prevention of calcium oxalate nephrolithiasis. Journal of Endourology 1999;13(9):679‐85. [MEDLINE: ] - PubMed
Ratan 2002
    1. Ratan SK, Bhatnagar V, Mitra DK, Basu N, Malhotra LK. Urinary citrate excretion in idiopathic nephrolithiasis. Indian Pediatrics 2002;39(9):819‐25. [MEDLINE: ] - PubMed
Sarada 1991
    1. Sarada B, Satyanarayana U. Urinary composition in men and women and the risk of urolithiasis. Clinical Biochemistry 1991;24(6):487‐90. [MEDLINE: ] - PubMed
Scales 2007
    1. Scales CD Jr, Curtis LH, Norris RD, Springhart WP, Sur RL, Schulman KA, et al. Changing gender prevalence of stone disease. Journal of Urology 2007;177(3):979‐82. [MEDLINE: ] - PubMed
Scales 2012
    1. Scales CD Jr, Smith AC, Hanley JM, Saigal CS, Urologic Diseases in America Project. Prevalence of kidney stones in the United States. European Urology 2012;62(1):160‐5. [MEDLINE: ] - PMC - PubMed
Schulz 2010
    1. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332. [MEDLINE: ] - PMC - PubMed
Schwille 1997
    1. Schwille PO, Schmiedl A, Herrmann U, Schwille R, Fink E, Manoharan M. Acute oral calcium‐sodium citrate load in healthy males. Effects on acid‐base and mineral metabolism, oxalate and other risk factors of stone formation in urine. Methods & Findings in Experimental & Clinical Pharmacology 1997;19(6):417‐27. [MEDLINE: ] - PubMed
Spivacow 2010
    1. Spivacow FR, Negri AL, Valle EE, Calviño I, Zanchetta JR. Clinical and metabolic risk factor evaluation in young adults with kidney stones. International Urology & Nephrology 2010;42(2):471‐5. [MEDLINE: ] - PubMed
Stamatelou 2003
    1. Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC. Time trends in reported prevalence of kidney stones in the United States: 1976‐1994. Kidney International 2003;63(5):1817‐23. [MEDLINE: ] - PubMed
Strauss 1982
    1. Strauss AL, Coe FL, Deutsch L, Parks JH. Factors that predict relapse of calcium nephrolithiasis during treatment: a prospective study. American Journal of Medicine 1982;72(1):17‐24. [MEDLINE: ] - PubMed
Sutherland 1985
    1. Sutherland JW, Parks JH, Coe FL. Recurrence after a single renal stone in a community practice. Mineral & Electrolyte Metabolism 1985;11(4):267‐9. [MEDLINE: ] - PubMed
Tiselius 1993
    1. Tiselius HG, Berg C, Fornander AM, Nilsson MA. Effects of citrate on the different phases of calcium oxalate crystallization. Scanning Microscopy 1993;7(1):381‐9. [MEDLINE: ] - PubMed
Trinchieri 1999
    1. Trinchieri A, Boccafoschi C, Chisena S, Angelis M, Seveso M. Study of the diuretic efficacy and tolerability of therapy with Rocchetta mineral water in patients with recurrent calcium kidney stones [Studio sulla tollerabilita e l'efficacia diuretica della idropinoterapia con acqua oligominerale Rocchetta in pazienti con nefrolitiasi calcica recidivante]. Archivio Italiano di Urologia, Andrologia 1999;71(2):121‐4. [MEDLINE: ] - PubMed
Turk 2014
    1. Türk C, Knoll T, Petrik A, Sarica K, Skolarikos A, Straub M, et al. Guidelines on urolithiasis. European Association of Urology. 2014. uroweb.org/wp‐content/uploads/22‐Urolithiasis_LR.pdf (accessed 26 August 2015).
Uribarri 1989
    1. Uribarri J, Oh MS, Carroll HJ. The first kidney stone. Annals of Internal Medicine 1989;111(12):1006‐9. [MEDLINE: ] - PubMed
Weisinger 1995
    1. Weisinger JR, Bellorı E. Experiencia Latino Americana em Litıase Renal Venezuela. In: Schor N, Pfeferman Heilberg I editor(s). Calculose Renal. Fisiopatologia, Diagnostico. Sao Paulo: Tratamiento, 1995:354–9.
Whalley 1996
    1. Whalley NA, Meyers AM, Martins M, Margolius LP. Long‐term effects of potassium citrate therapy on the formation of new stones in groups of recurrent stone formers with hypocitraturia. British Journal of Urology 1996;78(1):10‐4. [MEDLINE: ] - PubMed
Zuckerman 2009
    1. Zuckerman JM, Assimos DG. Hypocitraturia: pathophysiology and medical management. Reviews in Urology 2009;11(3):134‐44. [MEDLINE: ] - PMC - PubMed

References to other published versions of this review

Hanchanale 2012
    1. Hanchanale VS, Phillips R, Myatt A, Somani B, Nabi G, Biyani CS. Citrate salts for preventing and treating kidney stones. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD010057] - DOI - PMC - PubMed

LinkOut - more resources